Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

NCT00712829 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: 123-I-MIP-1072
DRUG: 123-I-MIP-1095

Sponsor

Molecular Insight Pharmaceuticals, Inc.